Print
Email
Print Edition StoriesThursday, December 17, 2009
Langer spinout Combinent lands VC funding
By Boston Business Journal staff
Robotic surgery gains traction
Funding drugs for rare diseases
MHT's Julie Donnelly: Life science startups finding investments
Drug-technology developer Combinent BioMedical Systems Inc. has closed a $500,000 round of venture capital.
The Lexington-based company, which specializes in the development of trans-vaginal drug-delivery technologies, said three investors participated in the equity round. The company’s polymer-based vaginal rings are designed to potentially dispense drugs for the treatment of women’s reproductive disorders as well as for diabetes, obesity and infectious diseases, according to the company’s website.
Combinent was founded by spinout titan Robert Langer, professor of chemical engineering at MIT, and William Crowley Jr., chief of the reproductive endocrine unit of the department of medicine at Massachusetts General Hospital.
Combinent closed a $3 million Series A round of venture capital in 2007. Investors at the time included VIMAC Ventures, Commons Capital, and Marlborough-based Cytyc Corp. through its Cytyc Development Co. LLC subsidiary.
Comments
If you are commenting using a Facebook account, your profile information may be displayed with your comment depending on your privacy settings. By leaving the 'Post to Facebook' box selected, your comment will be published to your Facebook profile in addition to the space below.
RSS Feeds
